RegeneRx PipelineRegeneRx Biopharmaceuticals, Inc. is a clinical-stage drug development company focused on tissue protection, repair and regeneration with an extensive portfolio of product candidates for first-in-class therapeutic peptides.
* In March 2011 the FDA placed a “clinical hold” on our Phase 2 AMI trial due to cGMP issues at a contract manufacturer’s site formulating RGN-352. The timing for the resumption of this trial is unclear. The reader is referred to our press releases dated March 16 and April 14, 2011. |
January 9, 2012
RegeneRx Issued Major U.S. Heart Patent
January 5, 2012
RegeneRx Receives Clinical Study Report for Phase 2 Dry Eye Trial
December 28, 2011
Status of Strategic Partnership Discussions Related to RGN-259 Ophthalmic Eye Drop
November 29, 2011
RegeneRx Receives Notice of Allowance on U.S. Patent for Skin Protection and Repair
November 17, 2011
RegeneRx Receives Notice of Allowance on Two Cardiac-Related Patent Applications
November 4, 2011
RegeneRx Answers Questions Regarding Phase 2 Dry Eye Trial